Communiqués Aptose Biosciences Inc. OTC Markets

Actions

APTO.F

CA03835T4081

Produits pharmaceutiques

Marché Fermé - OTC Markets Autres places de cotation 19:03:40 12/06/2026			Varia. 5j.	Varia. 1 janv.
1,612 ^USD	+2,71%		+2,71%	+8,95%

29/05	Aptose Biosciences : le rachat par Hanmi reporté au mois de juin	MT
29/05	Aptose Biosciences annonce un nouveau report de la finalisation de son accord avec Hanmi Pharmaceutical	RE

Communiqués

29/05	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
13/05	Aptose Biosciences: Q1 Earnings Snapshot	AQ
13/05	Aptose Biosciences : Reports First Quarter 2026 Results	PU
13/05	Aptose Reports First Quarter 2026 Results	AQ
30/04	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
01/04	Aptose Biosciences: Q4 Earnings Snapshot	AQ
31/03	Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights	AQ
23/03	Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement	AQ
20/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote FOR Proposed Plan of Arrangement with Hanmi Pharmaceutical	AQ
19/03	Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical	AQ
24/02	Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders	AQ
22/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC	AQ
19/12	Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC	AQ
06/12	Aptose Biosciences : TUSCANY Study Demonstrates Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Ineligible for Induction Chemotherapy	PU
06/12	Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations	AQ
19/11	Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical	AQ
13/11	Aptose Biosciences: Q3 Earnings Snapshot	AQ
13/11	Aptose Reports Third Quarter 2025 Results	AQ
03/11	Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting	AQ
16/10/25	Aptose Biosciences : ESH 2025 Poster - TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy	PU
16/10/25	Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML	AQ
22/09/25	Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML	AQ
22/08/25	Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor	AQ
21/08/25	Aptose Biosciences : TUS Triplet TUSCANY Trial Update - August 2025	PU
18/08/25	Aptose Biosciences : TUS Triplet TUSCANY Trial Update - August 2025	PU